

Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Crinecerfont

December 2025

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Crinecerfont

Dosage Form: Solution

Route: Oral

Strength: 50 mg/mL

Recommended Studies: Two options: (1) request for waiver of in vivo bioequivalence study requirements, or (2) two in vivo bioequivalence studies with pharmacokinetic endpoints

I. Option 1: Request for waiver of in vivo bioequivalence study requirements

To qualify for a waiver of the in vivo bioequivalence study requirement under 21 CFR 320.22(b)(3), generic versions of crinecerfont oral solution, 50 mg/mL, must contain the same active drug ingredient in the same concentration and dosage form as the reference listed drug and contain no difference in inactive ingredients or in other aspects of the formulation relative to the reference listed drug that may significantly affect the systemic availability of the active ingredient.

II. Option 2: Two in vivo bioequivalence studies with pharmacokinetic endpoints

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 50 mg/mL at a dose of 100 mg (2 mL)
Subjects: Healthy males and non-pregnant, non-lactating females
Additional comments:
 - Exclude subjects with abnormal complete blood counts due to the risk of neutropenia.
 - $AUC_{(0-72h)}$ may be used in place of $AUC_{(0-t)}$ for comparing the extent of absorption, due to crinicerfont's long half-life. Ensure adequate washout periods between treatments in the crossover study. Alternatively, a parallel study design may be considered.
2. Type of study: Fed
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 50 mg/mL at a dose of 100 mg (2 mL)
Subjects: Healthy males and non-pregnant, non-lactating females
Additional comments: See comments above.

Analyte to measure: Crinicerfont in plasma

Bioequivalence based on (90% CI): Crinicerfont

Dissolution test method and sampling times: Not applicable

Document History: Recommended December 2025

Unique Agency Identifier: PSG_218820